The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Outcomes of MPN patients versus non-MPN patients hospitalized for COVID-19
Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, discusses some findings from a retrospective analysis which compared the outcome of myeloproliferative neoplasm (MPN) patients who were hospitalized for COVID-19 versus non-MPN patients who were hospitalized for COVID-19. Dr Hobbs explains that hospitalized patients with MPNs had a higher incidence of thrombotic events compared to non-MPN patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
